
-
Asian markets edge up but uncertainty rules ahead of Trump tariffs
-
Nintendo's megahit Switch console: what to know
-
Nintendo to unveil upgrade to best-selling Switch console
-
China practises hitting key ports, energy sites in Taiwan drills
-
Oil, sand and speed: Saudi gearheads take on towering dunes
-
All eyes on Tsunoda at Japan GP after ruthless Red Bull move
-
'Image whisperers' bring vision to the blind at Red Cross museum
-
Hay shines as New Zealand make 292-8 in Pakistan ODI
-
Other governments 'weaponising' Trump language to attack NGOs: rights groups
-
UK imposes online entry permit on European visitors
-
How a Brazilian chief is staving off Amazon destruction
-
Meme politics: White House embraces aggressive alt-right online culture
-
China launches military drills in Taiwan Strait
-
US senator smashes record with 25-hour anti-Trump speech
-
Brazil binman finds newborn baby on garbage route
-
US senator smashes record with marathon anti-Trump speech
-
Trump advisor Waltz faces new pressure over Gmail usage
-
Niger junta frees ministers of overthrown government
-
Trump set to unleash 'Liberation Day' tariffs
-
Boeing chief to acknowledge 'serious missteps' at US Senate hearing
-
Real Madrid hold Real Sociedad in eight-goal thriller to reach Copa del Rey final
-
Nuno salutes 'special' Elanga after stunning strike fires Forest
-
PSG survive scare against Dunkerque to reach French Cup final
-
Sundowns edge Esperance as crowd violence mars quarter-final
-
Nottingham Forest beat Man Utd, Saka scores on Arsenal return
-
Elanga wonder-goal sinks Man Utd as Forest eye Champions League berth
-
Stock markets mostly advance ahead of Trump tariffs deadline
-
US movie theaters urge 45-day 'baseline' before films hit streaming
-
Saka scores on return as Arsenal beat Fulham
-
Third-division Bielefeld shock holders Leverkusen in German Cup
-
Ball-blasting 'Torpedo bats' making waves across MLB opening weekend
-
Newsmax shares surge more than 2,000% in days after IPO
-
Thousands of Hungarians protest against Pride ban law
-
GM leads first quarter US auto sales as tariffs loom
-
Tesla sales tumble in Europe in the first quarter
-
No 'eye for an eye' approach to US tariffs: Mexico
-
NFL club owners back dynamic kickoffs, delay tush push vote
-
Trump 'perfecting' new tariffs as nervous world braces
-
Trump nominee says to press UK on Israel arms
-
French court says Le Pen appeal ruling could come before presidential vote
-
The battle to control assets behind Bosnia crisis
-
Prabhsimran powers Punjab to IPL win over Lucknow
-
Mass layoffs targeting 10,000 jobs hit US health agencies
-
Tiger's April Foolishness: plan to play Masters just a joke
-
Myanmar quake toll passes 2,700, nation halts to honour victims
-
Turkish fans, artists urge Muse to cancel Istanbul gig
-
US seeks death penalty for accused killer of insurance CEO
-
UK govt moves to block sentencing guidelines for minority defendants
-
Trump puts world on edge as 'Liberation Day' tariffs loom
-
Swedish journalist jailed in Turkey kept 'isolated': employer

US tells pharmas to make Covid boosters targeting BA.4 and BA.5
The US Food and Drug Administration on Thursday told vaccine makers that Covid boosters for this fall and winter should include components targeting the BA.4 and BA.5 sublineages of Omicron.
Earlier this week, a panel of medical experts convened by the agency voted in favor of updating Covid vaccines against Omicron, with most indicating they would favor shots that target the latest iterations rather than its original form, BA.1, fearing the latter would be too out-of-date.
BA.4 and BA.5, which are more transmissible and immune evasive, now comprise more than 52 percent of US Covid cases, according to an official tracker.
"We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine," the FDA said in a statement.
These vaccines would also need to target the original Wuhan strain, in order to increase the breadth of immune response.
Pfizer and Moderna, which produce messenger RNA Covid vaccines, have developed and tested vaccines against BA.1, and representatives of both companies indicated during the experts' meeting they would need around three months to produce BA.4 and BA.5 vaccines at scale.
Pfizer shared early results showing its BA.4/5 vaccine produced a strong antibody response in mice, but it hasn't yet been trialed in humans.
Novavax, which makes a protein subunit vaccine, said it could offer BA.4/5 vaccines by the end of the year.
The FDA said in its new statement that the companies would need to submit human data prior to authorization.
The "primary series" or first shots a person receives would remain against the original strain, the FDA added.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sublineages have dominated throughout 2022, to the point it comprises the vast majority of all Covid in the world, FDA official Jerry Weir told the expert meeting this week.
This makes it more likely that the virus's future evolution will also occur along the Omicron branch of the Covid family tree, he added.
Earlier this month, the World Health Organization also recommended the use of Omicron boosters after a primary series against the original strain.
D.Sawyer--AMWN